BR0014712A - Uso de derivados carbonilamino contra distúrbios do snc - Google Patents

Uso de derivados carbonilamino contra distúrbios do snc

Info

Publication number
BR0014712A
BR0014712A BR0014712-5A BR0014712A BR0014712A BR 0014712 A BR0014712 A BR 0014712A BR 0014712 A BR0014712 A BR 0014712A BR 0014712 A BR0014712 A BR 0014712A
Authority
BR
Brazil
Prior art keywords
derivatives against
carbonylamino
hydrogen
disorders
carbonylamino derivatives
Prior art date
Application number
BR0014712-5A
Other languages
English (en)
Inventor
Vincent Mutel
Eric Vieira
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0014712A publication Critical patent/BR0014712A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE DERIVADOS CARBONILAMINO CONTRA DISTúRBIOS DO SNC". A presente invenção refere-se ao uso de derivados carbonilamino de fórmula geral ( I ) onde R significa alquila inferior, alquenila inferior, alquinila inferior, cicloalquila, alcóxi inferior ou CF~ 3~; R^ 1^ significa hidrogênio ou alquila inferior; R^ 2^ e R^ 3^ significam, independentemente um do outro, hidrogênio, halogênio ou nitro; Y significa CH ou N; n é 0-6; m é 0-2; bem como seus sais farmaceuticamente aceitáveis para o tratamento de doenças, o qual relacionam-se com antagonistas e/ou agonistas do receptor de glutamato metabotrópico.
BR0014712-5A 1999-10-12 2000-10-06 Uso de derivados carbonilamino contra distúrbios do snc BR0014712A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99120327 1999-10-12
PCT/EP2000/009781 WO2001027070A1 (en) 1999-10-12 2000-10-06 Use of carbonylamino derivatives against cns disorders

Publications (1)

Publication Number Publication Date
BR0014712A true BR0014712A (pt) 2002-06-18

Family

ID=8239189

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014712-5A BR0014712A (pt) 1999-10-12 2000-10-06 Uso de derivados carbonilamino contra distúrbios do snc

Country Status (18)

Country Link
US (1) US6548522B1 (pt)
EP (1) EP1224163B1 (pt)
JP (1) JP4098523B2 (pt)
KR (1) KR100468253B1 (pt)
CN (1) CN1184964C (pt)
AR (1) AR025990A1 (pt)
AT (1) ATE292107T1 (pt)
AU (1) AU775656B2 (pt)
BR (1) BR0014712A (pt)
CA (1) CA2388470C (pt)
DE (1) DE60019145T2 (pt)
DK (1) DK1224163T3 (pt)
ES (1) ES2238316T3 (pt)
MX (1) MXPA02003673A (pt)
PT (1) PT1224163E (pt)
TR (1) TR200200969T2 (pt)
WO (1) WO2001027070A1 (pt)
ZA (1) ZA200202437B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399641B1 (en) * 2000-07-13 2002-06-04 Hoffmann-La Roche Inc. 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
WO2003059873A1 (en) 2002-01-04 2003-07-24 Poseidon Pharmaceuticals A/S Potassium channel modulators
NZ582934A (en) 2007-08-02 2011-10-28 Recordati Ireland Ltd Novel heterocyclic compounds as mglu5 antagonists
JP2010536827A (ja) 2007-08-24 2010-12-02 ノイロサーチ アクティーゼルスカブ ある種の炎症性障害の治療に有用なカルボニルアミノ誘導体
EP2393780A1 (en) 2009-02-04 2011-12-14 Recordati Ireland Limited Heterocyclic derivatives as m-glu5 antagonists
WO2011029633A1 (en) 2009-09-14 2011-03-17 Recordati Ireland Limited Heterocyclic mglu5 antagonists
CN101786982A (zh) * 2010-03-30 2010-07-28 华东师范大学 一种合成2-吡啶基苯乙腈的方法
KR101862626B1 (ko) * 2010-07-09 2018-05-31 레코르다티 아일랜드 리미티드 Mglu5 대항체로서의 신 스피로헤테로사이클릭 화합물
BR112013015072A2 (pt) 2010-12-17 2016-07-12 Rhodes Technologies síntese de cloridrato de metilfenidato à baixa temperatura
CN110372530B (zh) * 2019-08-06 2021-07-30 郑州大学 一种含α取代苯基结构的化合物及其制备方法和消杀剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (pt) 1966-03-12
EP0474589A1 (de) 1990-08-02 1992-03-11 Ciba-Geigy Ag Orthophenolacetamide
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
JP3197822B2 (ja) 1996-01-31 2001-08-13 株式会社スリオンテック 可逆性感熱記録組成物とそれを用いた書き替え可能な可逆性感熱記録シートおよびカード
WO1997046511A1 (en) 1996-06-07 1997-12-11 Nps Pharmaceuticals, Inc. Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE69832302D1 (de) 1997-12-10 2005-12-15 Nps Pharma Inc Antikonvulsive und zns-aktive bis-fluoralkylamide

Also Published As

Publication number Publication date
DE60019145D1 (de) 2005-05-04
CA2388470A1 (en) 2001-04-19
EP1224163B1 (en) 2005-03-30
AU775656B2 (en) 2004-08-12
ATE292107T1 (de) 2005-04-15
DK1224163T3 (da) 2005-06-27
CN1378528A (zh) 2002-11-06
DE60019145T2 (de) 2006-01-26
EP1224163A1 (en) 2002-07-24
US6548522B1 (en) 2003-04-15
ES2238316T3 (es) 2005-09-01
CA2388470C (en) 2008-08-05
CN1184964C (zh) 2005-01-19
KR20020038947A (ko) 2002-05-24
AU7915100A (en) 2001-04-23
AR025990A1 (es) 2002-12-26
PT1224163E (pt) 2005-06-30
MXPA02003673A (es) 2002-08-30
KR100468253B1 (ko) 2005-01-27
ZA200202437B (en) 2003-09-23
TR200200969T2 (tr) 2002-07-22
WO2001027070A1 (en) 2001-04-19
JP4098523B2 (ja) 2008-06-11
JP2003511436A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
ATE399770T1 (de) Tachykininrezeptorantagonisten
BR0014712A (pt) Uso de derivados carbonilamino contra distúrbios do snc
BRPI0509761B8 (pt) compostos de quinolinona-carboxamida como agonistas de receptor de 5-ht4, composição farmacêutica, uso dos referidos compostos e seu processo de preparação
BR0311591A (pt) 1-(aminoalquil)-2-sulfonilazindóis como ligandos de 5-hidroxitriptamina-6
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
BG66085B1 (bg) Фенилаланинови производни
BR122018070508B8 (pt) derivados de arilamida triazol-substituída e seu uso
ECSP034640A (es) Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato
MY138352A (en) Benzothiazole derivatives
BRPI0409986A (pt) derivados de pirimidina fundida com atividade de crf
NO20020823L (no) Heteropolysykliske forbindelser og deres anvendelse som metabotropiske glutamatreseptorantagonister
BR0312940A (pt) Inibidores de quinases
HUP0204226A2 (en) Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds
NO20032208D0 (no) Benzodiazepinderivater som GABA A reseptormodulatorer
BR0206633A (pt) Derivados de 1-aril- ou 1-arilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6
BR0307406A (pt) Indóis substituìdos como agonistas alfa-1
DE60211343D1 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
BR9907169A (pt) "derivados de cabeça de ponte de piridila e seus análogos, composições farmacêuticas e seus empregos como inibidores de receptores colinérgicos nicotìnicos"
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
CY1105631T1 (el) Υποκατεστημενα παραγωγα καρβοστυριλης ως αγωνιστες 5-ητ1α υποτυπου δεκτη
BRPI0516467A (pt) derivados indol 5-sulfonil-1-piperidinil substituìdos como antagonistas de receptor de 5-ht6 para o tratamento de distúrbios do snc
NO990433L (no) Nye forbindelser og blandinger for behandling av sykdommer i forbindelse med tryptase-aktivitet
DK0923542T3 (da) Arylsubstituerede cycliske aminer som selektive dopamin-D3-ligander
CL2004000769A1 (es) Compuestos derivados del acido [2-(8,9-dioxo-2,6-diazabiciclo [5,2,o]non-1-(7)-en-2-il) alquil]fosfonico, antagonistas del receptor n-metil-d-aspartato (nmda); procedimiento de preparacion; composicion farmaceutica; y su uso para tratar desordenes va
DK1578740T3 (da) 1,2,4-triaminobenzenderivater, der er egnede til behandling af lidelser i centralnervesystemet

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: C07C 233/11, C07C 233/22, C07D 213/56, A61K 31/165

Ipc: A61K 31/165 (2009.01), C07C 233/11 (2009.01), C07C

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 11, 13, 24 E 25 DA LPI

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.